CIK as therapeutic agents against tumors

Area of Science:

• Immunology
• Cell Therapy
• Oncology

Background:

• Cytokine Induced Killer (CIK) cells are ex vivo expanded and activated T lymphocytes.
• They are derived from Peripheral Blood Mononuclear cells (PBMNC) through incubation with Interferon γ (IFNG), anti-CD3 monoclonal antibody OKT3, and IL2.
• CIK cells possess Natural Killer-like anti-tumoral cytotoxicity and exhibit potent intratumoral homing.

Purpose of the Study:

• To summarize the feasibility, toxicity, and efficacy of CIK cell adoptive transfer for cancer treatment.
• To discuss clinical protocols and future perspectives for optimizing CIK cell immunotherapy.

Main Methods:

• Ex vivo expansion and activation of PBMNC to generate CIK cells.
• Assessment of CIK cell characteristics, including cytotoxicity, homing, and allogeneic compatibility.
• Review of clinical protocols for CIK cell therapy in cancer patients.

Main Results:

• CIK cells demonstrate potent anti-tumoral activity in various experimental models and clinical settings.
• They exhibit extensive in vivo permanence and proliferation without significant toxicity to normal targets.
• Importantly, CIK cells do not induce Graft-versus-Host disease in allogeneic combinations.

Conclusions:

• CIK cell therapy is a feasible adoptive passive cell immunotherapy with limited toxicity.
• Preliminary efficacy has been observed in hematologic malignancies and against minimal residual disease.
• Future optimization may involve gene transfer technology or bispecific monoclonal antibodies.